TFS
BMY.RT

TrustCore Financial Services’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

TrustCore Financial Services’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-79
Closed – – 1028
2020
Q4 		$0 Hold
79
– – ﹤0.01% 983
2020
Q3 		$0 Hold
79
– – ﹤0.01% 959
2020
Q2 		$0 Hold
79
– – ﹤0.01% 980
2020
Q1 		$0 Hold
79
– – ﹤0.01% 997
2019
Q4 		$0 Buy
+79
New +$205 ﹤0.01% 1000

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

TrustCore Financial Services's BMY.RT Position: Q1 2021 in Review

TrustCore Financial Services sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 79 shares.

TrustCore Financial Services first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $0 in Q4 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • TrustCore Financial Services reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • TrustCore Financial Services sold 79 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021.
  • TrustCore Financial Services first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • TrustCore Financial Services's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $0 in Q4 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on TrustCore Financial Services's 13F filing for Q1 2021, filed 30 Apr 2021.